Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.66
XOMA's Cash to Debt is ranked lower than
83% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. XOMA: 0.66 )
Ranked among companies with meaningful Cash to Debt only.
XOMA' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.03 Max: No Debt
Current: 0.66
Equity to Asset -0.37
XOMA's Equity to Asset is ranked lower than
95% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XOMA: -0.37 )
Ranked among companies with meaningful Equity to Asset only.
XOMA' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.00 Max: 0.82
Current: -0.37
-0.77
0.82
F-Score: 1
Z-Score: -21.65
M-Score: 19.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -754.31
XOMA's Operating margin (%) is ranked lower than
75% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. XOMA: -754.31 )
Ranked among companies with meaningful Operating margin (%) only.
XOMA' s Operating margin (%) Range Over the Past 10 Years
Min: -433.75  Med: -151.05 Max: 13.17
Current: -754.31
-433.75
13.17
Net-margin (%) -458.79
XOMA's Net-margin (%) is ranked lower than
72% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. XOMA: -458.79 )
Ranked among companies with meaningful Net-margin (%) only.
XOMA' s Net-margin (%) Range Over the Past 10 Years
Min: -349.94  Med: -121.15 Max: 14.89
Current: -458.79
-349.94
14.89
ROA (%) -70.38
XOMA's ROA (%) is ranked lower than
80% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. XOMA: -70.38 )
Ranked among companies with meaningful ROA (%) only.
XOMA' s ROA (%) Range Over the Past 10 Years
Min: -108.21  Med: -51.27 Max: 4.68
Current: -70.38
-108.21
4.68
ROC (Joel Greenblatt) (%) -1034.39
XOMA's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. XOMA: -1034.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XOMA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1636.29  Med: -203.53 Max: 46.51
Current: -1034.39
-1636.29
46.51
Revenue Growth (3Y)(%) -55.70
XOMA's Revenue Growth (3Y)(%) is ranked lower than
86% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. XOMA: -55.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XOMA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.9  Med: -23.50 Max: 147.7
Current: -55.7
-60.9
147.7
EBITDA Growth (3Y)(%) -29.20
XOMA's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. XOMA: -29.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XOMA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.7  Med: -20.75 Max: 31.1
Current: -29.2
-39.7
31.1
EPS Growth (3Y)(%) -29.90
XOMA's EPS Growth (3Y)(%) is ranked lower than
79% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. XOMA: -29.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XOMA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53  Med: -15.00 Max: 36.7
Current: -29.9
-53
36.7
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

XOMA Guru Trades in Q2 2014

Louis Moore Bacon 75,000 sh (unchged)
Paul Tudor Jones Sold Out
John Burbank Sold Out
» More
Q3 2014

XOMA Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
» More
Q2 2015

XOMA Guru Trades in Q2 2015

Jim Simons 665,511 sh (New)
» More
Q3 2015

XOMA Guru Trades in Q3 2015

Paul Tudor Jones 64,225 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.80
XOMA's P/S is ranked higher than
54% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. XOMA: 8.80 )
Ranked among companies with meaningful P/S only.
XOMA' s P/S Range Over the Past 10 Years
Min: 0.55  Med: 5.97 Max: 39.33
Current: 8.8
0.55
39.33
Current Ratio 1.26
XOMA's Current Ratio is ranked lower than
86% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. XOMA: 1.26 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.03 Max: 6.65
Current: 1.26
0.63
6.65
Quick Ratio 1.26
XOMA's Quick Ratio is ranked lower than
81% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. XOMA: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.03 Max: 6.65
Current: 1.26
0.63
6.65
Days Sales Outstanding 1.00
XOMA's Days Sales Outstanding is ranked higher than
98% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. XOMA: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.81  Med: 77.46 Max: 226.37
Current: 1
26.81
226.37

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.47
XOMA's Price/Median PS Value is ranked lower than
75% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. XOMA: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
XOMA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 2.03 Max: 47.64
Current: 1.47
0.1
47.64
Price/Graham Number 0.54
XOMA's Price/Graham Number is ranked higher than
84% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. XOMA: 0.54 )
Ranked among companies with meaningful Price/Graham Number only.
XOMA' s Price/Graham Number Range Over the Past 10 Years
Min: 0.46  Med: 2.02 Max: 8.69
Current: 0.54
0.46
8.69
Earnings Yield (Greenblatt) (%) -40.50
XOMA's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. XOMA: -40.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XOMA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 7.6  Med: 14.40 Max: 19.6
Current: -40.5
7.6
19.6

More Statistics

Revenue(Mil) $12
EPS $ -0.46
Beta3.06
Short Percentage of Float19.08%
52-Week Range $0.69 - 4.93
Shares Outstanding(Mil)118.81

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 11 5 5 24
EPS($) -0.67 -0.25 -0.25 -0.29
EPS without NRI($) -0.67 -0.25 -0.25 -0.29

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany,
XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition Jan 04 2016
XOMA Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 24 2015
Direction of Market Influences - Research Reports on Iridium Communications, XOMA, Horsehead Holding... Dec 14 2015
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 09 2015
XOMA CORP Financials Dec 08 2015
XOMA Inks Agreement with Novo Nordisk for XMetA Program Dec 02 2015
Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million Dec 01 2015
4 Stocks to Watch Today that are Trading Under $500M Market Cap Dec 01 2015
[$$] Novo Nordisk Buys Xoma's Diabetes Treatment Dec 01 2015
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 01 2015
XOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes Dec 01 2015
XOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes Dec 01 2015
What Do Hedge Funds Think of Famous Dave’s of America, Inc. (DAVE)? Nov 29 2015
Is XOMA Corp (XOMA) A Good Stock To Buy? Hedge Funds Are Dumping It Nov 22 2015
Developments in the Equity Market - Research on United Online, Second Sight Medical Products, Five... Nov 20 2015
XOMA to Present at Two Upcoming Investor Conferences Nov 12 2015
XOMA to Present at Two Upcoming Investor Conferences Nov 12 2015
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Nov 12 2015
XOMA Corp (XOMA) Jumps: Stock Adds 24.4% in Session Nov 10 2015
Why Are These Four Stocks Gaining Ground on Monday? Nov 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK